Journal of Pharmacokinetics & Experimental Therapeutics
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Opinion   
  • J Pharmacokinet Exp Ther 2023, Vol 7(2): 174
  • DOI: 10.4172/jpet.1000174

Medication that Reduces Cholesterol by Preventing the body's Production of Cholesterol

Yoshio Tachiura*
Department of Applied Biological Chemistry, Graduate School of Agricultural and Life Sciences, The University of Ghutania, Japan
*Corresponding Author : Yoshio Tachiura, Department of Applied Biological Chemistry, Graduate School of Agricultural and Life Sciences, The University of Ghutania, Japan, Email: yoshio.tachiura@gmail.com

Received Date: Apr 03, 2023 / Published Date: Apr 27, 2023

Abstract

The Smith-Lemli-Opitz syndrome (SLOS) is a multiple malformation/mental retardation syndrome caused by a deficiency of the enzyme 7 dehydrocholesterol Δ7-reductase. This enzyme converts 7-dehydrocholesterol (7-DHC) to cholesterol in the last step in cholesterol biosynthesis. The pathology of this condition may result from two different factors: the deficiency of cholesterol itself and/or the accumulation of precursor sterols such as 7-DHC. Although cholesterol synthesis is defective in cultured SLOS cells, to date there has been no evidence of decreased whole body cholesterol synthesis in SLOS and only incomplete information on the synthesis of 7-DHC and bile acids. In this first report of the sterol balance in SLOS, we measured the synthesis of cholesterol, other sterols, and bile acids in eight SLOS subjects and six normal children. The diets were very low in cholesterol content and precisely controlled. Cholesterol synthesis in SLOS subjects was significantly reduced when compared with control subjects (8.6 vs. 19.6 mg/kg per day, respectively, P < 0.002).

Citation: Tachiura Y (2023) Medication that Reduces Cholesterol by Preventingthe body's Production of Cholesterol. J Pharmacokinet Exp Ther 7: 174. Doi: 10.4172/jpet.1000174

Copyright: © 2023 Tachiura Y. This is an open-access article distributed underthe terms of the Creative Commons Attribution License, which permits unrestricteduse, distribution, and reproduction in any medium, provided the original author andsource are credited.

Top